The 61 references in paper S. Sel'kov A., D. Sokolov I., S. Chepanov V., С. Сельков А., Д. Соколов И., С. Чепанов В. (2014) “ИММУНОРЕГУЛЯТОРНЫЕ ЭФФЕКТЫ ИММУНОГЛОБУЛИНОВ ДЛЯ ВНУТРИВЕННОГО ВВЕДЕНИЯ // IMMUNOREGULATORY EFFECTS OF INTRAVENOUS IMMUNOGLOBULINS” / spz:neicon:mimmun:y:2013:i:1:p:5-12

1
Аверченков В.М., Плагин И.С. Внутривенные иммуноглобулины: механизмы действия и возможности клинического применения // Клиническая микробиология антимикробная химиотерапия. – 2004. – No 3.
(check this in PDF content)
2
Веденеева Г.Н., Фоменко Б.А., Евсюкова И.И., Сельков С.А. Состояние и последующее развитие новорожденных детей от матерей с цитомегаловирусной инфекцией // Рос. вестник перинатологии и педиатрии. – 1997. – Т. 42, No 3. – С. 25-29.
(check this in PDF content)
3
Долгов В.В, Свирин П.В. Лабораторная диагностика нарушений гемостаза: учебное пособие. – М., 2005. – 195с.
(check this in PDF content)
4
Кондратенко И.В., Заплатников А.Л., Бологов А.А. Внутривенные иммуноглобулины: что и когда? // Детская больница. – 2010. – No 4.
(check this in PDF content)
5
Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии // Русский медицинский журнал. – 2006. – Специальный выпуск. – С. 2-10.
(check this in PDF content)
6
Мигунов В.Н., Ковалева Л.Г. Иммуноглобулины и их применение в клинической практике. Общая характеристика // www.blood.ru 30.01.06 г.
(check this in PDF content)
7
Насонов Е.Л. Антифосфолипидный синдром. – М.: Литтерра, 2004. – 440 с.
(check this in PDF content)
8
Румянцев А.Г. Основные свойства внутривенных иммуноглобулинов и показания к их применению // Вопросы онкологии, гематологии и иммунопатологии в педиатрии. – 2011. – Т. 10, No 2. – С. 39-50.
(check this in PDF content)
9
Сельков С.А., Селютин А.В., Зайнулина М.С. Влияние иммуномодулирующей терапии на клинико-лабораторные показатели беременных с невынашиванием и антифосфолипидным синдромом // Журнал акушерства и женских болезней. – 2011. – No 3. – С. 152-160.
(check this in PDF content)
10
Сидельникова В.М. «Привычная потеря беременности»: руководство. – М.: Триада-Х, 2000. – 304 с.
(check this in PDF content)
11
Ушкалова Е.А., Шифман Е.М. Проблема нерегламентированного применения иммуноглобулина для внутривенного введения в акушерстве // Акушерство и гинекология. – 2011. – No 3. – С. 74-80
(check this in PDF content)
12
Ярилин А.А. Иммунология: учебник. – М.: ГЭОТАР-Медиа, 2010. – 752 с.
(check this in PDF content)
13
Krupa A., Fudala R., Stankowska D. AntiChemokine Autoantibody: Chemokine Immune Complexes Activate Endothelial Cells via IgG Receptors // Am. J. Respir Cell Mol. Biol. – 2009. – Aug; 41 (2). – P. 155-169.
(check this in PDF content)
14
Kessel А., Ammuri H., Peri R. Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function // The J. of рисунок 2. Механизм индукции иммунологической толерантности внутривенными иммуноглобулинами примечание. ВВИГ – иммуноглобулины для внутривенного введения; IDO – индолил 2,3-диоксигеназа. ввиг CD200R блок клеточного цикла эндотелийэндотелийснижение пролиферации Т-клеток NK-клеток иммунологическая толерантность CD200CD200 IDO усиление апоптоза Т-клеток дендритная клетка катаболизм триптофана Immunology. – 2007. – Oct. 15; 179 (8). – P. 55715575
(check this in PDF content)
15
Arnout J., Jankowski M. Antiphospholipid syndrome // The Hematology J. – 2004. – N 5. – P. 1-5.
(check this in PDF content)
16
Blanchette V.S., Luke B., Andrew M. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura // J. Pediatr. – 1993. – Dec; 123 (6). – P. 989-95.
(check this in PDF content)
17
Chen Zhiqi. Cloning and characterization of the human CD200 promoter region // A thesis submitted in conformity with the requirements for the degree of Master of Science, Graduate Department of the Institute of Medical Science. – University of Toronto, 2001. – P. 85.
(check this in PDF content)
18
Chong B.H., Chong J.J. IVIg immune inhibitory activity: APC is key // Blood. – 2010. – Mar 4; 115 (9). – P. 1663-64.
(check this in PDF content)
19
Core SPC for human normal immunoglobulin for intravenous administration (IVIg) // European Medicines Agency Evaluation of Medicines for Human Use. London 2004. – July. – CPMP/ BPWG/859/95 rev. 2.
(check this in PDF content)
20
Criteria for the clinical use of intravenous immunoglobulin in Australia // Second Edition 2012.
(check this in PDF content)
21
Clark D.A., Wong K., Banwatt D. CD200dependent and nonCD200-dependant pathways of NK cell suppression by human IVIG // J. Assist. Reprod. Genet. – 2008. – March; 25(2-3). – P. 67-72.
(check this in PDF content)
22
Empson M.B, Lassere M. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant (Review) // The Cochrane Library 2011. – Issue 3.
(check this in PDF content)
23
Nimmerjahn F., Ravetch J.V. Fcγ receptors as regulators of immune responses // Nature Reviews Immunology. – 2007. – Vol. 8. – P. 34-47.
(check this in PDF content)
24
Fishman P., Bar-Yehuda S., Shoenfeld Y. IVIg to prevent tumor metastases // Int. J. Oncol. – 2002. – Oct; 21 (4). – P. 875-880.
(check this in PDF content)
25
Freiberger T., Grodecká L. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency // Clin Immunol. – 2010. – Sep; 136 (3). – P. 419-425.
(check this in PDF content)
26
Jacob H. Rand. Molecular Pathogenesis of the Antiphospholipid Syndrome // Circulation Research. – 2002. – January. – P. 29-37.
(check this in PDF content)
27
Jean-Eric Alard, Fanny Gaillard, Capucine Daridon. TLR2 Is One of the Endothelial Receptors for β2-Glycoprotein I // J. Immunol. – 2010. – Aug 1; 185 (3). – P. 1550-1557
(check this in PDF content)
28
Bayry J., Lacroix-Desmazes S., Carbonneil C. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin // Blood. – 2003. – Jan 15; 101 (2). – P. 758-765.
(check this in PDF content)
29
Harris E.N., Charavi A.E. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus // Ibid. – 1983. – Vol. 2. – P. 12111214.
(check this in PDF content)
30
Hughes G.R.V. Thrombosis, abortion, cerebral disease and lupus anticoagulant // Brit. Med. J. – 1983. – Vol. 187. – P. 1088-1089.
(check this in PDF content)
31
Human normal immunoglobulin for intravenous administration // European Pharmacopoeia PA/PH/Exp. 6B/T (11) 14 PUB.
(check this in PDF content)
32
Tanigaki K., Mineo Ch., Ivan S. C-Reactive Protein Inhibits Insulin Activation of Endothelial Nitric Oxide Synthase via the Immunoreceptor Tyrosine-Based Inhibition Motif of FcγRIIB and SHIP-1 // Circ. Res. – 2009. – June 5; 104 (11). – P. 1275-1282.
(check this in PDF content)
33
Damianovich M., Blank M., Raiter A. Antivascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) // International Immunology. – 2009. – Vol. 21, N 9. – P. 1057-1063.
(check this in PDF content)
34
Meroni P.L., Borghi M.O. Pathogenesis of antiphospholipid syndrome: understanding the antibodies // Nat. Rev. Rheumatol. – 2011. – Jun; 7 (6). – P. 330-39.
(check this in PDF content)
35
Miletic VD, Hester CG and Frank MM. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes // The J. of Immunology. – 1996. – Vol. 156, Issue 2. – P. 749-757.
(check this in PDF content)
36
Goebl N.A., Babbey C.M. Neonatal Fc Receptor Mediates Internalization of Fc in Transfected Human Endothelial Cells // Mol. Biol. Cell. – 2008. – December; 19 (12). – P. 5490-5505.
(check this in PDF content)
37
Dussault N., Ducas E., Racine C. Immunomodulation of human B cells following treatment with intravenous immunoglobulins involves increased phosphorylation of extracellular signal-regulated kinases 1 and 2 // International Immunology. – 2008. – Vol. 20, N 11. – P. 1369-1379.
(check this in PDF content)
38
Barclay N., Gavin J. CD200 and membrane protein interactions in the control of myeloid cells // Trends in Immunology. – 2002. – Vol. 23, Issue 6, 1 June. – P. 285-290.
(check this in PDF content)
39
Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. // N. Engl. J. Med. – 2005. – N 353. – P. 1350-62.
(check this in PDF content)
40
Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox // J. Exp Med. – 2007. – Jan 22; 204 (1). – P. 11-15.
(check this in PDF content)
41
Nimmerjahn F., Ravetch J.V. Fcg Receptors: Old Friends Review and New Family Members // Immunity. – 2006. – Jan 24. – P. 19-28.
(check this in PDF content)
42
Oates-Whitehead R.M., Baumer J.H., Haines L., Love S. Intravenous immunoglobulin for the treatment of Kawasaki disease in children // Cochrane Database Syst. Rev. – 2003; (4): CD004000.
(check this in PDF content)
43
Travers P., Walport M., Shlomchik M. Immunobiology: By Charles Janeway. – 2004. – 6th Edition
(check this in PDF content)
44
Porter T.F., La Coursiere Y., Scott J.R. Immunotherapy for recurrent miscarriage: review The Cochrane Collaboration. – 2010.
(check this in PDF content)
45
Radulescu L., Antohe F. Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells // Hum. Immunol. – 2004 . – June; 65 (6). – P. 578-585.
(check this in PDF content)
46
Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor // Science. – 2001. – Jan 19; 291 (5503). – P. 484-486.
(check this in PDF content)
47
Sewell W.A.C., Jolles S. Immunomodulatory action of intravenous immunoglobulin // Immunology. – 2002. – December; 107 (4). – P. 387393.
(check this in PDF content)
48
Sewell W.A.C., North M.E., Cambronero R. In vivo modulation of cytokine synthesis by intravenous immunoglobulin // Clin. Exp. Immunol. – 1999. – June; 116 (3). – P. 509-515.
(check this in PDF content)
49
Vielma S., Virella G., Gorod A.J. Chlamydophila pneumoniae Infection of Human Aortic Endothelial Cells Induces the Expression of FC-Receptor II (Fc_RII) // Clinical Immunology. – 2002. – Vol. 104, N 3, September. – P. 265-273.
(check this in PDF content)
50
Devaraj S., Davis B., Simon S.I. CRP promotes monocyte-endothelial cell adhesion via Fc_ receptors in human aortic endothelial cells under static and hear flow conditions // Am. J. Physiol. Heart Circ. Physiol. – 2006. – Sep; 291 (3). – P. 1170-1176.
(check this in PDF content)
51
Stephenson M.D., Kutteh W.H. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebocontrolled trial // Human Reproduction. – 2010. – Vol. 25, N 9. – P. 2203-2209
(check this in PDF content)
52
Tha-In T., Metselaar H.J. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells // Blood. – 2007. – Vol. 110, N 9. – P. 3253-62.
(check this in PDF content)
53
Arumugam T.V., Tang S.-C. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complementmediated neuronal cell death // PNAS. – 2007. – Vol. 104, N 35. – P. 14104-14109.
(check this in PDF content)
54
Tripodi A., de Groot P.G., Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment // J. of Internal Medicine. – 2011. – Aug 270 (2). – P. 110-22.
(check this in PDF content)
55
Urbanus R.T., de Groot P.G. Antiphospholipid antibodies--we are not quite there yet // Blood Rev. – 2011. – Mar; 25 (2). – P. 97-106.
(check this in PDF content)
56
Gill V., Doig Ch., Knight D. Targeting Adhesion Molecules as a Potential Mechanism of Action for Intravenous Immunoglobulin // Vascular Medicine. – 2005. – 112 (13). – P. 2031-2039.
(check this in PDF content)
57
Wim K., Jessica L., Teeling C. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect // Blood. – 2001. – Vol. 98, N 10. – P. 3136-3142.
(check this in PDF content)
58
Wong R.C., Favaloro E.J. Clinical features, diagnosis, and management of the antiphospholipid syndrome // Thromb Hemost. – 2008. – Apr; 34 (3). – P. 295-304.
(check this in PDF content)
59
Wright G.J., Cherwinski H., Foster-Cuevas M. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200 // J. Immunol. – 2003. – Sep 15; 171 (6) – P. 3034-46.
(check this in PDF content)
60
Xu C, Poirier B. Modulation of endothelial cell function by normal polyspecific human intravenous immunoglobulins: a possible mechanism of action in vascular diseases // Am. J. Pathol. – 1998. – Oct; 153 (4). – P. 1257-66.
(check this in PDF content)
61
Shoenfeld Y., Levy Y., Fishman P. Shrinkage of Melanoma Metastases Following High Dose Intravenous Immunoglobulin Treatment // IMAJ. – 2001. – Vol. 3. – P. 698-699. поступила в редакцию 19.06.2012
(check this in PDF content)